Description:
Developing robust pharmaceutical production processes to ensure patient safety and drug efficacy is dependent on the sound understanding and control of the drug substance and drug product quality attributes relevant for clinical performance and drug product manufacture. This understanding is then translated into the design of the manufacturing process and a relevant monitoring and control system to ensure that quality attributes within the desired ranges are consistently obtained. This session covers both drug substance and drug product critical quality attribute identification, characterization, and monitoring systems for quality and manufacturing process control. Authors are encouraged to highlight clinically relevant specifications for pharmaceutical products and innovative control strategies for drug substance and drug product manufacturing.
Sponsor:
Pharmaceutical Discovery, Development and Manufacturing Forum
Co-Sponsor(s):
Product Design (12G), Pharmaceuticals (15B)
Chair:
Huiquan Wu
Chemical Engineer
FDA/CDER
OPQ/OPF
LS64 Room 1080
Silver Spring, MD
20993
Phone Number: 3017960022
Fax Number: 301-796-9816
Email: huiquan.wu@fda.hhs.gov
Chemical Engineer
FDA/CDER
OPQ/OPF
LS64 Room 1080
Silver Spring, MD
20993
Phone Number: 3017960022
Fax Number: 301-796-9816
Email: huiquan.wu@fda.hhs.gov
Co-Chair:
Otute Akiti
Senior Director
Relypsa, Inc
Drug Substance Manufacturing & Development
Redwood City, CA
Phone Number: 650.421.9511
Fax Number: 650.421.9711
Email: oakiti@relypsa.com
Senior Director
Relypsa, Inc
Drug Substance Manufacturing & Development
Redwood City, CA
Phone Number: 650.421.9511
Fax Number: 650.421.9711
Email: oakiti@relypsa.com
Papers:
Abstract Submissions Closed
See more of this Group/Topical: Pharmaceutical Discovery, Development and Manufacturing Forum
